The COVID-19 and Influenza A+B antigen rapid test is a rapid immunoassay for the qualitative detection of antigens to the SARS-CoV-2, Influenza A and Influenza B virus. For its operation, it uses nasopharyngeal swab samples from individuals suspected of being affected by SARS-CoV-2. Or they have an influenza infection along with the clinical presentation and results of other laboratory tests.
Samples for rapid detection of COVID 19 and Influenza
For the detection of COVID-19, an antigen is usually found in upper airway samples during the acute phase of infection. Positive results indicate the presence of viral antigens in the person. But, be careful, a clinical correlation with the patient’s history and other diagnostic information is necessary to determine the status of the infection.
Positive results that may be obtained do not rule out bacterial infection or co-infection with other viruses. And it is possible that the agent detected is not the definitive cause of the disease.
On the other hand, negative results in such an analysis do not exclude SARS-CoV-2 or Influenza A B infection and should not be used as the basis for the diagnosis of treatment or for making management decisions.
Therefore, it is always recommended that negative results be treated as presumptive and confirmed with a molecular assay.
COVID 19 Combined Quick Test
The COVID-19 and Influenza A+B rapid antigen test in combination is designed for use by staff working in a trained clinical laboratory.
This test is a qualitative membrane-based immunoassay for the detection of SARS-CoV-2 antigens in a human nasopharyngeal swab sample. To do this, the antibody SARS-CoV-2 is coated in the test line regionDuring the COVID-19 rapid antigen test, the sample reacts with particles coated with antibodies to SARS-CoV-2 that have been placed. This causes the mixture to migrate up on the membrane by capillary action and react with the SARS-CoV-2 antibody in the test line.
Quality controls the rapid test of COVID-19 antigen and Influenza A+B
If the sample contains SARS-CoV-2 antigens, a color line appears in the test line region. If the sample does not contain antigens, no color line appears.
To serve as a control, a colored line will always appear in the control region, indicating that the appropriate sample volume has been added. And of course, the membrane absorption has occurred.
In this test, antibodies specific to influenza A and influenza B nucleoproteins are coated separately in the test line.
During the test, the specimen removed to the person reacts with influenza A and/or B antibodies covering the particles. The mixture migrates to the membrane to react with influenza A and/or B antibodies and to generate one or two colored lines in the test regions.
The presence of this color line in one or both of the test regions indicates a positive result. To control the procedure, we will always have a colored line in the control region if the test was successful.
At Durviz we know how important it is to have tests of this kind in your laboratory. That’s why we put it at your fingertips on our website. So if you want to buy them, you should contact us.